| 000 | 01583 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518081604.0 | ||
| 264 | 0 | _c20210305 | |
| 008 | 202103s 0 0 eng d | ||
| 022 | _a1941-837X | ||
| 024 | 7 |
_a10.1080/13696998.2020.1717499 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPinheiro, Bernardete | |
| 245 | 0 | 0 |
_aCost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. _h[electronic resource] |
| 260 |
_bJournal of medical economics _cMay 2020 |
||
| 300 |
_a484-491 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 |
_aCladribine _xadverse effects |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFingolimod Hydrochloride _xadverse effects |
| 650 | 0 | 4 |
_aHealth Expenditures _xstatistics & numerical data |
| 650 | 0 | 4 |
_aHealth Resources _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 | _aPortugal |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 700 | 1 | _aGuerreiro, Rita | |
| 700 | 1 | _aCosta, João | |
| 700 | 1 | _aMiguel, Luís Silva | |
| 773 | 0 |
_tJournal of medical economics _gvol. 23 _gno. 5 _gp. 484-491 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/13696998.2020.1717499 _zAvailable from publisher's website |
| 999 |
_c30532363 _d30532363 |
||